Moreover, the 36-month beta value for VERA is 1.15. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for VERA is 48.99M and currently, short sellers hold a 13.88% of that float. On January 09, 2025, VERA’s average trading volume was 729.71K shares.
VERA) stock’s latest price update
Vera Therapeutics Inc (NASDAQ: VERA)’s stock price has gone rise by 0.21 in comparison to its previous close of 42.10, however, the company has experienced a -0.24% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-01-07 that BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 – 16, 2025. The management team will also participate in one-on-one investor meetings.
VERA’s Market Performance
Vera Therapeutics Inc (VERA) has experienced a -0.24% fall in stock performance for the past week, with a -12.94% drop in the past month, and a 9.19% rise in the past quarter. The volatility ratio for the week is 3.45%, and the volatility levels for the past 30 days are at 4.64% for VERA. The simple moving average for the past 20 days is -1.98% for VERA’s stock, with a 3.62% simple moving average for the past 200 days.
Analysts’ Opinion of VERA
Many brokerage firms have already submitted their reports for VERA stocks, with Wells Fargo repeating the rating for VERA by listing it as a “Overweight.” The predicted price for VERA in the upcoming period, according to Wells Fargo is $70 based on the research report published on November 21, 2024 of the previous year 2024.
Oppenheimer gave a rating of “Outperform” to VERA, setting the target price at $26 in the report published on January 25th of the previous year.
VERA Trading at -7.21% from the 50-Day Moving Average
After a stumble in the market that brought VERA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.25% of loss for the given period.
Volatility was left at 4.64%, however, over the last 30 days, the volatility rate increased by 3.45%, as shares sank -11.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.68% upper at present.
During the last 5 trading sessions, VERA fell by -0.24%, which changed the moving average for the period of 200-days by +2.90% in comparison to the 20-day moving average, which settled at $43.04. In addition, Vera Therapeutics Inc saw -0.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VERA starting from MARSHALL FORDYCE, who proposed sale 17,500 shares at the price of $42.10 back on Jan 08 ’25. After this action, MARSHALL FORDYCE now owns shares of Vera Therapeutics Inc, valued at $736,750 using the latest closing price.
Fordyce Marshall, the PRESIDENT AND CEO of Vera Therapeutics Inc, sale 17,500 shares at $43.07 during a trade that took place back on Dec 18 ’24, which means that Fordyce Marshall is holding 85,942 shares at $753,680 based on the most recent closing price.
Stock Fundamentals for VERA
The total capital return value is set at -0.42. Equity return is now at value -65.11, with -49.39 for asset returns.
Based on Vera Therapeutics Inc (VERA), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.39. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -21.33.
Currently, EBITDA for the company is -102.01 million with net debt to EBITDA at -0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.60.
Conclusion
To wrap up, the performance of Vera Therapeutics Inc (VERA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
